Apoptosis in cancer: from pathogenesis to treatment
Top Cited Papers
Open Access
- 26 September 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Experimental & Clinical Cancer Research
- Vol. 30 (1), 87-14
- https://doi.org/10.1186/1756-9966-30-87
Abstract
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. It is also one of the most studied topics among cell biologists. An understanding of the underlying mechanism of apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. In some, the problem is due to too much apoptosis, such as in the case of degenerative diseases while in others, too little apoptosis is the culprit. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. The mechanism of apoptosis is complex and involves many pathways. Defects can occur at any point along these pathways, leading to malignant transformation of the affected cells, tumour metastasis and resistance to anticancer drugs. Despite being the cause of problem, apoptosis plays an important role in the treatment of cancer as it is a popular target of many treatment strategies. The abundance of literature suggests that targeting apoptosis in cancer is feasible. However, many troubling questions arise with the use of new drugs or treatment strategies that are designed to enhance apoptosis and critical tests must be passed before they can be used safely in human subjects.Keywords
This publication has 100 references indexed in Scilit:
- Overexpression of survivin initiates hematologic malignancies in vivoLeukemia, 2010
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancerProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeted rescue of a destabilized mutant of p53 by an in silico screened drugProceedings of the National Academy of Sciences of the United States of America, 2008
- Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 ActivatorCancer Cell, 2008
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibitionProceedings of the National Academy of Sciences of the United States of America, 2008
- Cell Death: Critical Control PointsCell, 2004
- The Hallmarks of CancerCell, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- Bcl-xL forms an ion channel in synthetic lipid membranesNature, 1997
- The p53 tumour suppressor geneNature, 1991